Bristol-Myers Squibb Company (BMY) |
|
68.07 0.39 (0.58%)
|
03-27 16:00 |
|
Open: |
68.09 |
Pre. Close: |
67.68 |
|
High:
|
68.82 |
Low:
|
68.01 |
|
Volume:
|
6,689,785 |
Market Cap:
|
143,172(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:17:49 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 81.08 One year: 84.07 |
| Support: |
Support1: 65.27 Support2: 54.31 |
| Resistance: |
Resistance1: 69.42 Resistance2: 71.98 |
| Pivot: |
67.05  |
| Moving Average: |
MA(5): 67.5  MA(20): 67.57
MA(100): 73.41 MA(250): 73.75 |
| MACD: |
MACD(12,26): -0.9 Signal(9): -1.2 |
| Stochastic oscillator: |
%K(14,3): 55.1 %D(3): 48.3 |
| RSI: |
RSI(14): 47.3 |
| 52-week: |
High: 81.44 Low: 65.27 |
| Average Vol(K): |
3-Month: 8,141 (K) 10-Days: 8,955 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BMY ] has closed below upper band by 11.0%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
67.81 - 68.14 |
68.14 - 68.48 |
|
Low:
|
65.9 - 66.25 |
66.25 - 66.6 |
|
Close:
|
67.12 - 67.67 |
67.67 - 68.23 |
|
Company Description |
|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
Headline News |
Mon, 27 Mar 2023
Bristol-Myers Squibb: Nobody Panic! Share Price Stumble Shouldn't ... - Seeking Alpha
Mon, 27 Mar 2023
Bristol Myers Squibb: Unraveling The Complexities Of Valuation - Seeking Alpha
Sun, 26 Mar 2023
Ellsworth Advisors LLC Acquires 1754 Shares of Bristol-Myers ... - MarketBeat
Fri, 24 Mar 2023
Wesbanco Bank Inc. Boosts Stock Holdings in Bristol-Myers Squibb ... - MarketBeat
Wed, 22 Mar 2023
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer? - Forbes
Wed, 15 Mar 2023
Bristol Myers Squibb Announces Progress Toward Long-Term ... - Bristol-Myers Squibb
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
2,100 (M) |
| Shares Float |
2,100 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
78.8 (%) |
|
Shares Short
|
17,020 (K) |
|
Shares Short P.Month
|
20,720 (K) |
Stock Financials |
|
EPS
|
2.91 |
|
EPS Est Next Qtl
|
0.79 |
|
EPS Est This Year
|
3 |
|
EPS Est Next Year
|
3.23 |
|
Book Value (p.s.)
|
14.81 |
|
Profit Margin (%)
|
13.7 |
|
Operating Margin (%)
|
21.3 |
|
Return on Assets (ttm)
|
5.9 |
|
Return on Equity (ttm)
|
18.9 |
|
Qtrly Rev. Growth
|
-4.9 |
|
Gross Profit (p.s.)
|
17.32 |
|
Sales Per Share
|
21.98 |
|
EBITDA (p.s.)
|
9.6 |
|
Qtrly Earnings Growth
|
-11.4 |
|
Operating Cash Flow
|
13,070 (M) |
|
Levered Free Cash Flow
|
13,830 (M) |
Stock Valuations |
|
PE Ratio
|
23.4 |
|
PEG Ratio
|
2 |
|
Price to Book value
|
4.59 |
|
Price to Sales
|
3.09 |
|
Price to Cash Flow
|
10.94 |
Stock Dividends |
|
Dividend
|
0.56 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.8% |
|
Dividend Pay Date
|
2022-01-31 |
|
Ex-Dividend Date
|
2022-01-05 |
|
Your Ad Here
|
|
